QUESTION MARK ICON

QUESTIONS?

CONTACT US
Group 4

Conquering Chronic Inflammation Today

FOR A BETTER TOMORROW

 

 

FDA ACCEPTS HEALTHBIOAI LONG COVID CLINICAL TRIAL  JANUARY, 2024

Group 1

We have identified a common thread in chronic inflammatory diseases through the use of machine learning and AI-based precision diagnostics. 

 

This work has led to the creation of our patented diagnostic testing and pharmaceutical treatment platform.

MOLECULE ILLU - WHITE
IMAGE (3) View Case Study on Machine Learning

HealthBioAI has discovered the root cause for diagnosing and treating chronic inflammatory diseases with patient's suffering from:

FATIGUE

BRAIN FOG

HEADACHE
OR MIGRAINE

JOINT PAIN

MUSCLE PAIN
AND WEAKNESS

EXERCISE
INTOLERANCE

Group 2

OUR MISSION

Develop solutions for millions of patients suffering from chronic inflammatory diseases worldwide

TODAY: WE ARE PURSUING THE DIAGNOSis AND TREATMENT Of CHRONIC INFLAMMATORY
DISEASES AND DISORDERS

INCIDENCE OF PREVALENT INFLAMMATORY

DISEASES/DISORDERS IN THE US

Group 47553

LONG COVID

22Million
Group 47554

CHRONIC LYME

476K
Group 47555

FIBROMYALGIA

4Million
Group 47552

CHRONIC FATIGUE
SYNDROME (ME/CFS)

2.5Million

Tomorrow: Our ongoing research and development includes Oncology, Alzheimer's and Autoimmune Diseases

Group 3

Executing the same clinical algorithm developed with our machine learning and AI Health Data platform allows us to pursue diagnosis and treatment solutions for many other chronic inflammatory diseases.

Pic 1 for home page
Group 3 (1)

HealthBioAI has cracked the code by identifying the molecular root cause of Long Covid and potentially other inflammatory diseases.

 

In Long Covid patients, the SI protein of the COVID-19 virus remains in their white blood cells, leading to a persistent immune response despite the absence of the active COVID-19 infection.

 

These white blood cells have many CCR5 and fractalkine receptors on their cell surface, which promote vascular inflammation and immune dysregulation through the monocytic-endothelial-platelet axis. We believe this is the primary root cause for adverse symptoms.

user rating with photo-Mar-29-2024-09-48-45-3631-AM

RESOURCE ARTICLE

Frontiers in Immunology

Persistent of Sars CoV-2 S1 Protein in CD16+ Monocytea in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection

READ MORE Group 47508

HEALTHBIOAI LOGO

Message from CEO video

MESSAGE FROM CEO

Dr. Bruce Patterson, Founder & CEO

CLICK TO VIEW
Press Release

PRESS RELEASE

FDA acceptance of clinical trial for Long Covid

CLICK TO VIEW

1. Davis H, Assaf G, McCorkell L, Wei H, Low R, Re'em Y, et al. Characterizing long COVID in a international cohort: 7 months of symptoms and their impact. EClinicalMedicine. (2021) 38:101019. do: 10.1016/j.eclinm.2021.10109

 

2. Nearly One in Five American Adults Who Have Had COVID-9 Still Have "Long COVID".
https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.html

 

3. Worldometer: COVID-19 CORONAVIRUS PANDEMIC.
https://www.worldometers.info/coronavirus/e

 

4. Surveillance for Lyme Disease - United States, 2008-2015
https://www.cdc.gov/mmwr/volumes/66/ss/ss6622al.htm?s_cid=ss6622al_W

 

5. Arthritis Types: Fibromyalgia.
https://www.cdc.gov/arthritis/types/fibromyalgia.htm

 

6. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
https://www.cdc.gov/me-cfs/index.html